Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 120 results for multiple sclerosis

  1. Functional electrical stimulation for drop foot of central neurological origin (IPG278)

    Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.

    Interventional procedures guidance
    Published
    28 January 2009
    View recommendations

    Sections for IPG278

  2. Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) (IPG188)

    Evidence-based recommendations on deep brain stimulation for tremor and dystonia (excluding Parkinson's disease). This involves planting electrodes in the brain and generating electrical currents to help control the tremor or dystonia.

    Interventional procedures guidance
    Published
    23 August 2006
    View recommendations

    Sections for IPG188

  3. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    dysfunction, as well as those with spinal cord injury, spina bifida and multiple sclerosis. Reports of its use in other conditions are...

    Research recommendation
    Published
    9 June 2015

  4. Management strategies to reduce the risk of symptomatic urinary tract infections:- In people with neurogenic lower urinary tract dysfunction, which management strategies (including the use of prophylactic antibiotics and various invasive and non-invasive techniques to aid bladder drainage) reduce the risk of symptomatic urinary tract infections?

    renal function. In the population with neurological diseases such as multiple sclerosis, Parkinson's disease and dementia, the rise in...

    Research recommendation
    Published
    9 June 2015

  5. Self-expanding implant insertion into the intersphincteric space for faecal incontinence (IPG685)

    Evidence-based recommendations on self-expanding implant insertion into the intersphincteric space for faecal incontinence. This involves inserting implants that expand and press together, forming a ring that creates an artificial sphincter.

    Interventional procedures guidance
    Published
    27 January 2021
    View recommendations

    Sections for IPG685

  6. Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention (IPG536)

    Evidence-based recommendations on sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention. This involves implanting a stimulator device into the upper buttock to restore the ability to empty the bladder voluntarily.

    Interventional procedures guidance
    Published
    25 November 2015
    View recommendations

    Sections for IPG536

  7. Tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions) (IPG299)

    Evidence-based recommendations on tenotomy of horizontal eye muscles for nystagmus (with reattachment at their original insertions). This involves cutting the horizontal muscles of the eye (which move the eye from side to side) and reattaching them at the same place.

    Interventional procedures guidance
    Published
    27 May 2009
    View recommendations

    Sections for IPG299

  8. Transabdominal artificial bowel sphincter implantation for faecal incontinence (IPG276)

    Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.

    Interventional procedures guidance
    Published
    26 November 2008
    View recommendations

    Sections for IPG276

  9. Safety and efficacy of antimuscarinics:- What is the safety and efficacy of more recently developed antimuscarinics compared with (a) placebo/usual care and (b) other antimuscarinics in the treatment of neurogenic lower urinary tract dysfunction?

    adults with impaired cognition (caused by cerebral involvement in multiple sclerosis or neurodegenerative diseases). Source guidance...

    Research recommendation
    Published
    9 June 2015

  10. CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes (MIB48)

    NICE has developed a medtech innovation briefing (MIB) on the CORTRAK 2 Enteral Access System for placing nasoenteral feeding tubes .

    Medtech innovation briefing
    Last updated
    9 December 2016

  11. Insertion of a magnetic bead band for faecal incontinence (IPG483)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

    Interventional procedures guidance
    Published
    27 March 2014
    View recommendations

    Sections for IPG483

  12. Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)

    NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .

    Medtech innovation briefing
    Published
    18 January 2017

  13. HIV testing: encouraging uptake (QS157)

    This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    7 September 2017
    View quality statements

    Sections for QS157

  14. RT300 for spinal cord injury rehabilitation (MIB169)

    NICE has developed a medtech innovation briefing (MIB) on RT300 for spinal cord injury rehabilitation .

    Medtech innovation briefing
    Published
    16 January 2019

  15. Multiple sclerosis: Management of multiple sclerosis in primary and secondary care (CG8)

    This guidance has been updated and replaced by NICE guideline CG186.

    Clinical guideline
    Published
    26 November 2003